Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich to Market Protein Arrays Made by Procognia

NEW YORK, Nov. 9 (GenomeWeb News) - Sigma-Aldrich will market human protein arrays developed by Procognia, the companies said today.

Procognia has developed a tag technology to create arrays of biologically related human proteins that retain their native functions in the array format, the companies said. The first array will contain wild type human p53 and its germline SNP variants.


Procognia's SNP-variant proteins will enable researchers to investigate the mechanism of cancer progression on many proteins in parallel, the company said.


Additional protein arrays, expected to launch "in the coming months," will contain "selected sets of biologically related human proteins including collections of proteins associated with key diseases including cancer and signal transduction," according to a statement.


Financial terms of the exclusive collaboration were not disclosed.


Separately, Sigma said it has declared a quarterly cash dividend of $.17 per share. The dividend is payable on Dec. 15 to shareholders of record on Dec. 1, 2004.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.